Leukemia

Patients with acute myeloid leukemia who opted for biomarker-based treatment achieved better outcomes than those who opted for standard chemotherapy, according to results of the Beat AML Master Clinical Trial published in Nature Medicine.

Children with very low-risk acute lymphoblastic leukemia can be treated successfully with reduced-intensity therapy, according to results of a study published in Blood.

The FDA cleared an investigational new drug application for PMB-101, a chimeric antigen receptor T-cell therapy, for the treatment of refractory or relapsed B-cell acute lymphoblastic leukemia.

Allogeneic or “off-the-shelf” chimeric antigen receptor T-cell therapies have moved into early-phase clinical testing with the hope that they will offer many advantages over autologous regimens.

Four Cleveland Clinic oncology staff members have been appointed to new roles at Taussig Cancer Institute.

CTX110 exhibited clinical activity among patients with advanced B-cell lymphoma, according to topline data from a phase 1 dose-escalation trial released by the agent’s manufacturer.

Chimeric antigen receptor T-cell therapies are the apex of a practice-changing shift in the treatment of acute lymphoblastic leukemia, according to a presenter at NCCN 2020 Virtual Congress: Hematologic Malignancies.

A chemotherapy-free first-line treatment strategy led to high rates of molecular response and survival among a subset of adults with acute lymphoblastic leukemia, according to study results published in The New England Journal of Medicine.

The FDA granted fast track designation to the combination of ublituximab and umbralisib for the treatment of adults with chronic lymphocytic leukemia, according to a press release from the drugs’ manufacturer.

The FDA granted full approval to venetoclax in combination with azacitidine, decitabine or low-dose cytarabine to treat certain patients with newly diagnosed acute myeloid leukemia.